North America Antibodies Market

North America Antibodies Market Size (2023 to 2032)

The North America Antibodies Market was valued at USD 63.55 billion in 2023. The North America Antibodies Market is expected to have 12.45 % CAGR from 2024 to 2032 and be worth USD 182.71 billion by 2032 from USD 71.46 billion in 2024.  

The market for antibodies in North America is majorly driven by continuous development of innovative products, increased adoption rate to therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses owing to population shift and rising longevity, rapid approval by regulatory authorities for breakthrough therapies, and adoption of diagnostic antibodies. Companies are adopting various strategies, like the expansion of product indications to sustain the dynamically growing market.

The antibodies market is a very fast-growing market in terms of research, and there is constant innovation in the field. Constant innovation of newer innovative products is therefore known to drive the demand in the market. Also, very cost-sensitive markets are now adapting to the therapeutic antibodies, increasing the demand for the antibodies.

The epidemiological transition from acute to chronic illnesses and increased life expectancy in North America has increased the demand for antibodies in the long run. The fertile environment for the new therapeutic antibodies, government policies are further helping the industry to flourish. The companies adapt to the changing market and orient their business plan and policies to help increase the antibodies sector.

The high cost of treatment and side effects associated with antibody treatment are the restraints that affect the market's growth.

This research report on the North American antibodies market has been segmented and sub-segmented into the following categories

North America Antibodies Market - By Product Type

• Monoclonal Antibodies

  • Murine

  • Chimeric
  • Humanized
  • Human
• Polyclonal Antibodies
  • Type I
  • Type II
  • Type III
  • Type IV
  • Type V
  • Type VI
  • Type VII
  • Type VIII
• Anti-body drug complexes
  • Immunogen Technology
  • Seattle Genetics Technology
  • Immunomedics Technology

North America Antibodies Market - By Indication

• Cancer

• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Other)

North America Antibodies Market - By End User

• Hospitals/Clinics

• Research institute

• Diagnostics laboratories

North America Antibodies Market - By Application

• Medical

• Experimental

• Western blot
• ELISA
• Radioimmune Assays
• Immunofluorescence
• Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

North America Antibodies Market - By Country

• The United States

• Canada

• Rest of North America

Geographically, in 2023, North America dominated the global antibodies market with a share of 39.7%. This is due to increased research in the domains of proteomics and genomics and the existence of major biopharmaceutical and biotechnology companies.

The market in North America is growing because of the rising incidence of cardiovascular disease, increased need for antibodies for research reproductivity, government investments in improving healthcare expenses, and increased development efforts to create better diagnostic therapy. Investing in medicines and improving healthcare infrastructure

These antibodies can be used to develop medicinal therapies and test immunoassays. Immunoassay tests are used to determine if a certain antigen or antibody is present in a patient's blood or other fluid samples. It's frequently utilized in novel drug development, drug monitoring, and food sample testing.

The Canadian antibodies market is also estimated to increase its market growth in the upcoming years with the government's help.

KEY MARKET PLAYERS

A few promising companies in the North American antibodies market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and company, A.G. Scientific, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.